Therapeutic response to radiofrequency ablation of neoplastic lesions: FDG PET/CT findings

Radiographics

Volumn 31, Issue 1, 2011, Pages

  Purandare, Nilendu C ^a   Rangarajan, Venkatesh ^a   Shah, Sneha A ^a   Sharma, Anshu R ^a   Kulkarni, Suyash S ^a   Kulkarni, Aniruddha V ^a   Dua, Sumeet G ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

BONE TUMOR; CATHETER ABLATION; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LIVER TUMOR; LUNG TUMOR; METASTASIS; POSITRON EMISSION TOMOGRAPHY; REVIEW;

BONE NEOPLASMS; CATHETER ABLATION; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79953802482     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.311105033     Document Type: Article

References (48)

1. Schima W, Kulinna C, Langenberger H, Ba-Ssalamah A. Liver metastases of colorectal cancer: US, CT or MR? Cancer Imaging 2005;5(Spec No A): S149-S156.
2. Bipat S, van Leeuwen MS, Comans EF, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta-analysis. Radiology 2005; 237(1):123-131.
3. Quaia E, D'Onofrio M, Palumbo A, Rossi S, Bruni S, Cova M. Comparison of contrast-enhanced ultrasonography versus baseline ultrasound and contrastenhanced computed tomography in metastatic disease of the liver: diagnostic performance and confidence. Eur Radiol 2006;16(7):1599-1609.
4. Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 2004;45(1):56-68.
5. Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003;44(2):224-239.
6. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005; 46(6):983-995.
7. Gazelle GS, Goldberg SN, Solbiati L, Livraghi T. Tumor ablation with radio-frequency energy. Radiology 2000;217(3):633-646.
8. Antoch G, Vogt FM, Veit P, et al. Assessment of liver tissue after radiofrequency ablation: findings with different imaging procedures. J Nucl Med 2005;46 (3):520-525.
9. Goldberg SN, Dupuy DE. Image-guided radiofrequency tumor ablation. I. Challenges and opportunities. J Vasc Interv Radiol 2001;12(9):1021-1032.
10. Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF. To enhance or not to enhance? 18FFDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med 2004;45(suppl 1): 56S-65S.
11. Khandani AH, Calvo BF, O'Neil BH, Jorgenson J, Mauro MA. A pilot study of early 18F-FDG PET to evaluate the effectiveness of radiofrequency ablation of liver metastases. AJR Am J Roentgenol 2007; 189(5):1199-1202.
12. Kuehl H, Antoch G, Stergar H, et al. Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. Eur J Radiol 2008;67 (2):362-371.
13. Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000;32(5): 792-797.
14. Torizuka T, Tamaki N, Inokuma T, et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994;35(12):1965-1969.
15. Donckier V, Van Laethem JL, Goldman S, et al. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol 2003;84(4):215-223.
16. Langenhoff BS, Oyen WJ, Jager GJ, et al. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 2002;20(22):4453-4458.
17. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995;19(1):59-71.
18. Fernando HC, De Hoyos A, Landreneau RJ, et al. Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates. J Thorac Cardiovasc Surg 2005;129(3): 639-644.
19. Herrera LJ, Fernando HC, Perry Y, et al. Radiofrequency ablation of pulmonary malignant tumors in nonsurgical candidates. J Thorac Cardiovasc Surg 2003;125(4):929-937.
20. Dupuy DE, Mayo-Smith WW, Abbott GF, DiPetrillo T. Clinical applications of radio-frequency tumor ablation in the thorax. RadioGraphics 2002; 22(Spec Issue):S259-S269.
21. Simon CJ, Dupuy DE, DiPetrillo TA, et al. Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology 2007;243(1): 268-275.
22. Thanos L, Mylona S, Pomoni M, et al. Percutaneous radiofrequency thermal ablation of primary and metastatic lung tumors. Eur J Cardiothorac Surg 2006;30(5):797-800.
23. Steinke K, King J, Glenn D, Morris DL. Radiologic appearance and complications of percutaneous computed tomography-guided radiofrequencyablated pulmonary metastases from colorectal carcinoma. J Comput Assist Tomogr 2003;27(5): 750-757.
24. Bojarski JD, Dupuy DE, Mayo-Smith WW. CT imaging findings of pulmonary neoplasms after treatment with radiofrequency ablation: results in 32 tumors. AJR Am J Roentgenol 2005;185(2):466-471.
25. Okuma T, Matsuoka T, Yamamoto A, Hamamoto S, Nakamura K, Inoue Y. Assessment of early treatment response after CT-guided radiofrequency ablation of unresectable lung tumours by diffusionweighted MRI: a pilot study. Br J Radiol 2009;82 (984):989-994.
26. Sewell PE Jr, Vance RB, Wang YD. Assessing radiofrequency ablation of non-small cell lung cancer with positron emission tomography (PET) [abstr]. Radiology 2000;217(P):334.
27. Akeboshi M, Yamakado K, Nakatsuka A, et al. Percutaneous radiofrequency ablation of lung neoplasms: initial therapeutic response. J Vasc Interv Radiol 2004;15(5):463-470.
28. Okuma T, Okamura T, Matsuoka T, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: preliminary results. Ann Nucl Med 2006;20(2):115-121.
29. Higaki F, Okumura Y, Sato S, et al. Preliminary retrospective investigation of FDG-PET/CT timing in follow-up of ablated lung tumor. Ann Nucl Med 2008;22(3):157-163.
30. Choi D, Lim HK, Kim MJ, et al. Liver abscess after percutaneous radiofrequency ablation for hepatocellular carcinomas: frequency and risk factors. AJR Am J Roentgenol 2005;184(6):1860-1867.
31. Akahane M, Koga H, Kato N, et al. Complications of percutaneous radiofrequency ablation for hepatocellular carcinoma: imaging spectrum and management. RadioGraphics 2005;25(Spec Issue):S57-S68.
32. Rhim H, Yoon KH, Lee JM, et al. Major complications after radio-frequency thermal ablation of hepatic tumors: spectrum of imaging findings. Radio-Graphics 2003;23(1):123-134, discussion 134-136.
33. de Baère T, Risse O, Kuoch V, et al. Adverse events during radiofrequency treatment of 582 hepatic tumors. AJR Am J Roentgenol 2003;181(3):695-700.
34. Okuma T, Matsuoka T, Okamura T, et al. 18F-FDG small-animal PET for monitoring the therapeutic effect of CT-guided radiofrequency ablation on implanted VX2 lung tumors in rabbits. J Nucl Med 2006;47(8):1351-1358.
35. Yamamoto A, Nakamura K, Matsuoka T, et al. Radiofrequency ablation in a porcine lung model: correlation between CT and histopathologic findings. AJR Am J Roentgenol 2005;185(5):1299-1306.
36. Woertler K, Vestring T, Boettner F, Winkelmann W, Heindel W, Lindner N. Osteoid osteoma: CT-guided percutaneous radiofrequency ablation and followup in 47 patients. J Vasc Interv Radiol 2001;12(6): 717-722.
37. Rosenthal DI, Springfield DS, Gebhardt MC, Rosenberg AE, Mankin HJ. Osteoid osteoma: percutaneous radio-frequency ablation. Radiology 1995; 197(2):451-454.
38. Barei DP, Moreau G, Scarborough MT, Neel MD. Percutaneous radiofrequency ablation of osteoid osteoma. Clin Orthop Relat Res 2000;373:115-124.
39. Rosenthal DI, Hornicek FJ, Wolfe MW, Jennings LC, Gebhardt MC, Mankin HJ. Percutaneous radiofrequency coagulation of osteoid osteoma compared with operative treatment. J Bone Joint Surg Am 1998;80(6):815-821.
40. Rosenthal DI, Hornicek FJ, Torriani M, Gebhardt MC, Mankin HJ. Osteoid osteoma: percutaneous treatment with radiofrequency energy. Radiology 2003;229(1):171-175.
41. Petsas T, Megas P, Papathanassiou Z. Radiofrequency ablation of two femoral head chondroblastomas. Eur J Radiol 2007;63(1):63-67.
42. Martel Villagrán J, Bueno Horcajadas A, Ortiz Cruz EJ. Percutaneous radiofrequency ablation of benign bone tumors: osteoid osteoma, osteoblastoma, and chondroblastoma [in Spanish]. Radiologia 2009;51 (6):549-558.
43. Liu PT, Chivers FS, Roberts CC, Schultz CJ, Beauchamp CP. Imaging of osteoid osteoma with dynamic gadolinium-enhanced MR imaging. Radiology 2003;227(3):691-700.
44. Imperiale A, Moser T, Ben-Sellem D, Mertz L, Gangi A, Constantinesco A. Osteoblastoma and osteoid osteoma: morphofunctional characterization by MRI and dynamic F-18 FDG PET/CT before and after radiofrequency ablation. Clin Nucl Med 2009;34(3):184-188.
45. Feldman F, van Heertum R, Manos C. 18FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol 2003;32(4):201-208.
46. Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001; 219(3):774-777.
47. Lim CH, Park YH, Lee SY, Chung SK. F-18 FDG uptake in the nidus of an osteoid osteoma. Clin Nucl Med 2007;32(8):628-630.
48. Mungo DV, Zhang X, O'Keefe RJ, Rosier RN, Puzas JE, Schwarz EM. COX-1 and COX-2 expression in osteoid osteomas. J Orthop Res 2002;20(1): 159-162.